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Abstract: Ph+ ALL is a poor-prognosis leukemia subtype driven by the BCR-ABL1 oncogene, either
the p190- or the p210-BCR/ABL isoform in a 70:30 ratio. Tyrosine Kinase inhibitors (TKIs) are
the drugs of choice in the therapy of Ph+ ALL. In combination with standard chemotherapy, TKIs
have markedly improved the outcome of Ph+ ALL, in particular if this treatment is followed by
bone marrow transplantation. However, resistance to TKIs develops with high frequency, causing
leukemia relapse that results in <5-year overall survival. Thus, new therapies are needed to address
relapsed/TKI-resistant Ph+ ALL. We have shown that expression of cell cycle regulatory kinase
CDK6, but not of the highly related CDK4 kinase, is required for the proliferation and survival of Ph+
ALL cells. Comparison of leukemia suppression induced by treatment with the clinically-approved
dual CDK4/6 inhibitor palbociclib versus CDK6 silencing revealed that the latter treatment was
markedly more effective, probably reflecting inhibition of CDK6 kinase-independent effects. Thus, we
developed CDK4/6-targeted proteolysis-targeting chimeras (PROTACs) that preferentially degrade
CDK6 over CDK4. One compound termed PROTAC YX-2-107, which degrades CDK6 by recruiting
the Cereblon ubiquitin ligase, markedly suppressed leukemia burden in mice injected with de novo
or TKI-resistant Ph+ ALL. The effect of PROTAC YX-2-107 was comparable or superior to that of
palbociclib. The development of CDK6-selective PROTACs represents an effective strategy to exploit
the “CDK6 dependence” of Ph+ ALL cells while sparing a high proportion of normal hematopoietic
progenitors that depend on both CDK6 and CDK6 for their survival. In combination with other
agents, CDK6-selective PROTACs may be valuable components of chemotherapy-free protocols for
the therapy of Ph+ ALL and other CDK6-dependent hematological malignancies.
Keywords: cell cycle; kinase; apoptosis; chemotherapy; proteolysis-targeting chimeras (PROTACs)
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1. Introduction
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized
by abnormal proliferation of progenitor cells of the lymphoid lineage. ALL displays a
bi-modal age distribution with a first peak of incidence around 1 to 4 years and a second
peak after 55 years of age [1]. B-ALL accounts for about 90% of pediatric and 75% of adult
cases, while the remaining cases are of T-cell lineage [2].
Adult B-ALL has, in general, a dismal outcome with long-term cure rates that have
only modestly improved over the past decades and remain less than 20%. In particular,
elderly patients exhibit reduced tolerance for high-dose chemotherapy and a higher frequency of treatment-related mortality [3]. By contrast, infant and pediatric B-ALL cases
have better cure rates [4,5]. B-ALL 5-year relative survival rate varies by age: For adults
ages 20 and older, the rate is 38% for ALL; for youth ages 0–19 years, it is 89% for ALL.
B-ALL is a heterogeneous disease with a complex molecular pathogenesis that differs
in children and adults, and involves an array of genetic aberrations including mutations
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and chromosomal translocations of genes with essential roles in the cell cycle and lymphoid
cell development. The mechanisms of the disease in children and adults depend, in most
cases, on aberrant expression of transcription factors (TFs) or the constitutive activations of
kinases that promote the acquisition of self-renewal, and are responsible for the enhanced
proliferation and the differentiation arrest of lymphoid progenitor cells [6].
Some disease subtypes have a worse than average outcome and are known as “highrisk B-ALL”. In adults, the most frequent ‘high-risk’ subtype is the Philadelphia-positive
(Ph+) ALL which is characterized by the reciprocal t(9;22) (q34;q11) translocation involving
the BCR and the ABL1 genes. The BCR-ABL1 fusion genes generate the BCR-ABL chimeric
protein that has constitutive tyrosine kinase activity and serves as the biological driver as
well as the therapeutic target of the disease [7].
About a quarter of B-ALL patients do not present with prototypical mutations, chromosomal translocations or karyotypic abnormalities and as such were traditionally defined
as B-others. More recently, transcriptome analyses revealed that a consistent fraction of
these cases exhibit expression profiles similar to those of Ph+ ALL. This subtype was
originally identified independently by two groups and was defined as Philadelphia (Ph)like [8] or as BCR-ABL1-like [9]. Ph-like ALL constitutes 15–25% of total B-ALL, therefore
accounting for the majority of B-other cases, is associated with poor-prognosis and its
frequency increases with age in a manner similar to Ph+ ALL [10,11]. The Ph-like ALL is
also a “high-risk” subtype with a <25% 5-year survival.
Similarly to Ph+ ALL, Ph-like ALL patients show frequent alterations of IKFZ1 and
CDKN2A, both of which confer resistance to therapy and correlate with poor outcome.
Molecularly, the vast majority, if not all cases of Ph-like ALL, harbor alterations in genes
conferring de-regulated kinase-activity; in particular, translocations involving the CRLF2
gene are observed in about half of the cases and generate fusion proteins or lead to increased CRLF2 expression driven by the immunoglobulin heavy-chain (IgH) enhancer [12].
Other common translocations involve ABL1, CSF1R, PDGFRB, EPOR or JAK2. Frequent
mutations are also observed in the IL7R, FLT3, JAK1 and JAK2 genes. Most of the aforementioned mutations activate signal transduction pathways that appear to converge on
STAT5. Depending on the molecular abnormality driving specific subtypes of Ph-like
ALL, pharmacological targeting of the activated signaling pathways may be a promising
therapeutic option for Ph-like ALL. Indeed, TKI inhibitors such as Imatinib/Dasatinib,
mTOR inhibitors and JAK inhibitors have been effective in pre-clinical studies and are
currently under investigation in the clinic [10].
Many new drugs including TKIs, immune checkpoint inhibitors, cell cycle inhibitors,
monoclonal antibodies targeting B-cell markers, pro-apoptotic and epigenetic agents are
currently under investigation in the clinic. Use of these promising agents, alone or in
combination with standard cytotoxic agents, has dramatically broadened the therapeutic
opportunities for B-ALL patients, improving clinical outcomes. In this review, we focus
on the therapeutic strategies for Ph+ ALL with a special emphasis on inhibitors of cellcycle kinases.
2. Mechanisms of Transformation by the BCR-ABL Oncoprotein
Three BCR-ABL fusion proteins can derive from the rearranged genes of Philadelphia
translocation, depending on the breakpoint on the BCR gene. When the break occurs in
the major breakpoint of BCR (M-bcr) the 50 of BCR up to exon 13 (also known as b2) or
exon 14 (also known as b3) is fused to the ABL1 gene in the first intron to generate the
p210 BCR-ABL isoform. If the break occurs in the minor breakpoint of BCR (m-bcr) the
first exon of BCR (e1) is fused to the first intron of the ABL1 gene generating the p190
BCR-ABL isoform. Less frequently, the break can occur in the micro breakpoint of BCR (µbcr) which includes the BCR gene up to exon 19, generating the p230 BCR-ABL. The three
BCR-ABL1 fusion genes and the resulting chimeric proteins are associated with different
leukemia subtypes (Figure 1). Chronic myeloid leukemia (CML) is almost exclusively
associated with expression of the p210BCR-ABL isoform while in Ph+ B-ALL about three
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mechanism for MYC activation in Ph+ ALL which depends on STAT5-mediated activation
of PIM1 [27]. Two additional pathways downstream of BCR-ABL have been thoroughly
characterized, the PI3K-AKT pathway [28] and the RAS pathway leading to activation of
ERK [29,30] or of c-JUN/JNK [31].
Compared to CML, Ph+ ALL is characterized by a much higher frequency of secondary
mutations and chromosomal abnormalities, in particular translocations.
Secondary mutations in Ph+ ALL are, in part, associated with enhanced activity of the
activation-induced cytidine deaminase AICDA (expressing AID) gene. Genes that appear
to be mutated through this mechanism include the IgH variable (V) region genes, BCL6,
and CDKN2B [32].
Another mechanism implicated in the genomic instability of BCR-ABL-expressing cells
is their increased production of reactive oxygen species (ROS) [33]. Such an increase appears
to be caused by the constitutive tyrosine kinase activity of BCR-ABL via a STAT5-dependent
pathway and is associated with an increased frequency of BCR-ABL mutations [34,35].
Although there are no specific studies in Ph+ ALL, it is likely that activation of STAT5
mediated by the constitutively active BCR-ABL tyrosine kinase is also involved in a ROSdependent mechanism of enhanced mutagenesis of the BCR-ABL gene.
In conclusion, the expression of BCR-ABL1 in hematopoietic stem cells and B-cell progenitors results in leukemia formation by several mechanisms converging in the promotion
of cell proliferation, resistance to apoptosis and the acquisition of secondary mutations.
3. Therapy of Ph+ ALL
3.1. A. Chemotherapy
The Philadelphia chromosome is a marker of poor outcome in pediatric and adult
B-ALL [36–38]. Prior to the development of BCR-ABL TKIs, Ph+ ALL had a dismal outcome
with a 1-year survival of approximately 10% [39]. Today, the combination of new TKIs with
chemotherapy, the improvement in stem cell transplantation and the availability of novel
immunotherapeutic strategies has greatly improved patients’ outcome.
Chemotherapy in combination with TKIs is currently the standard treatment for Ph+
ALL. Typically, the treatment of de novo Ph+ ALL is divided in three phases: induction of
remission, intensification/consolidation and maintenance [40,41]. The induction phase is
the most aggressive phase of the therapeutic regimen and its aim is to reduce as much as
possible patients’ leukemia burden and restoring normal hematopoiesis. Minimal residual
disease (MRD) after the induction phase is typically monitored by high-sensitivity methods,
which detect leukemic cells at a frequency of 1 × 10−4 or lower, such as flow cytometry
analysis of leukemia-specific surface markers or qPCR to identify leukemia-specific BCRABL1 transcripts.
The achievement of MRD-negative status is the most important predictor of clinical
outcome and can inform therapeutic decisions [42]. Another important factor is the localization of the disease in the central nervous system (CNS) that cannot be reached efficiently
by most drugs and can serve as a reservoir of leukemic cells resulting in relapse. For this
reasons, CNS-prophylaxis (intrathecal therapy or CNS irradiation) is usually included in
the treatment protocol [43,44]. The induction phase includes agents such as vincristine
(microtubule destabilizing agent), anthracyclines such as doxorubicin or daunorubicin
(topoisomerase II inhibitors) and asparaginase (agent depleting asparagine which is essential for lymphoid cells), often conjugated with PEG to increase drug half-life. A common
therapeutic protocol, named hyper-CVAD, consist of hyper-fractioned doses of cyclophosphamide (DNA-cross-linking agent), vincristine, doxorubicin and dexamethasone [45].
Glucocorticoids (dexamethasone and prednisone) are frequently used in association with
chemotherapy. They function as ligands for the glucocorticoid receptor, which, upon activation, induces an endogenous immunosuppressive program leading to cell cycle arrest and
apoptosis. Their advantage includes the ability to pass the blood-brain barrier providing
activity in the CNS; on the other hand, being immunosuppressive agents, their use is
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associated with morbidity and mortality due to infections and may also cause psychiatric
symptoms and bone toxicity [46].
After the induction phase, eligible patients in complete remission and with an appropriate donor undergo bone marrow transplantation. Bone marrow transplantation
remains, to date, a curative treatment for young patients affected by Ph+ ALL, especially
for those who achieve undetectable minimal residual disease (MRD) after induction therapy [47]. Maintenance therapy with tyrosine kinase inhibitors (TKIs) after transplantation
is well tolerated and may reduce the risk if relapse, and is thus frequently incorporated in
post-transplant regimens, despite a lack of consensus [48,49].
For Ph+ ALL patients who are not eligible for bone marrow transplantation, the
consolidation/maintenance phase includes treatment with methotrexate (anti-folate agent)
and mercaptopurine (inhibitor of de-novo nucleotide synthesis) with pulses of vincristinedexamethasone [41].
3.2. B. BCR-ABL Tyrosine Kinase Inhibitors (TKIs)
The first specific inhibitor for the BCR-ABL tyrosine kinase was developed in 1996.
imatinib (known originally as CGP-57148, STI-571 and subsequently as Glivec) was shown
to inhibit BCR-ABL and the non-translocated ABL, as well as the PDGFRa/b and c-KIT
but not other SRC-family proteins or other kinases, functioning as a competitive ATP
binding inhibitor [50,51]. In vitro, imatinib markedly suppressed the viability of BCR-ABL
expressing cells with no effect against normal cell lines and bone marrow cells [51]. In
CML patients, imatinib induced a complete hematologic response (normalization of white
blood cell count) in all cases and a major cytogenetic response (reduction in the number of
Ph+ cells in the bone marrow) in 54% of patients [52]. Currently, treatment with imatinib is
associated with >10-year survival and major cytogenetic response in approximately 33% of
CML patients [7].
In patients with CML-myeloid blast crisis and CML-lymphoid blast crisis/Ph+ ALL,
treatment with imatinib showed an early response with a marked reduction of circulating
or bone marrow leukemic cells. However, in contrast to CML, the effect was transient
with almost all patients relapsing within 6 months of treatment [53]. It was immediately
apparent that imatinib resistance was associated, in most cases, with mutations in the
tyrosine kinase domain of BCR-ABL and in some cases with BCR-ABL amplification [54].
In particular, the T315 mutation in the ABL kinase domain which blocks the access of
imatinib to the ATP binding site was frequently observed.
Second generation TKIs, including nilotinib and dasatinib, were subsequently developed. Nilotinib is structurally very similar to imatinib and has the same spectrum of
activity toward tyrosine kinases. Dasatinib has several advantages over other TKIs: (i) it
is about 300-fold more potent than imatinib; (ii) it is active against SRC-kinases; (iii) in
contrast to imatinib and nilotinib, it binds BCR-ABL in the active conformation; and (iv) it
is not a substrate of the P-glycoprotein (which mediate multi-drug resistance) [55]. Notably,
dasatinib is the only TKI shown to pass the blood-brain barrier, potentially protecting
against CNS relapse [56]. When tested in imatinib-resistant or intolerant CML-chronic
phase patients, dasatinib induced a complete hematologic response and a major cytogenetic
response in 92% of patients.
Responses were sustained in 95% of patients with a median follow-up of more than
12 months. In Ph+ ALL patients, 70% showed a complete hematologic response and a
cytogenetic response. However, as seen with other TKIs, relapse was observed in all cases
within 6 months [57]. The T315I mutation of BCR-ABL is the Achilles’ heel of TKIs since it
is the most common secondary mutation and confers resistance to imatinib and all secondgeneration inhibitors [58]. Ponatinib, a third-generation BCR-ABL TKI, was introduced in
2013 and was shown to be active against the T315I BCR-ABL mutant. In the first clinical
trial, ponatinib induced a complete hematologic response and a major cytogenetic response
in 94% and 46% respectively, of CML-chronic phase patients who failed a previous therapy
with a TKI and had the T315I mutation in 24% of the cases. With a median follow-up of
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15 months, almost all patients remained in remission. Conversely, in Ph+ ALL, complete
hematologic response and cytogenetic response were observed in 41% and 38% of patients
respectively. However, almost all patients relapsed within 12 months [59]. In Ph+ ALL
patients, ponatinib was directly compared to dasatinib as frontline therapy in a treatment
regimen including hyper-CVAD and showed improved 3-year event-free survival and
overall survival (83% for ponatinib vs 56% for dasatinib) [60]. By studying the mechanism
of resistance, it became clear that no single, direct point mutation confers resistance to
ponatinib; however, compound mutations or the subsequent mutation of isoleucine 315
into a methionine renders BCR-ABL insensitive to ponatinib treatment [61].
It is also apparent that mutations of BCR-ABL are more common in Ph+ ALL than
in CML blasts which may explain the higher rates of treatment failure in Ph+ ALL. Interestingly, secondary BCR-ABL mutations in Ph+ ALL might be associated with aberrant
expression of the AICDA gene which induces C to T transitions that could generate the
T315I, E255K and Y253H mutations [58].
In summary, the chemotherapy/ponatinib combination represents an option for the
treatment of Ph+ ALL, but the side effects of ponatinib, in particular cardiovascular toxicity,
are significant [62]. A limitation of BCR-ABL targeting therapies is the development of
BCR-ABL-independent resistance through poorly understood mechanisms. In the majority
of cases, Ph+ ALL exhibits the deletion of the IKZF1 gene [63], which encodes a TF that
mediates pre-B-cell receptor signaling, inducing tumor suppression. The deletion of IKZF1
is associated with more frequent and early-onset relapses [8,64]. Similarly, CDKN2A
deletion is associated with poor response to therapy probably through a process of clonal
selection during treatment with TKIs [65,66]. Another factor that confers resistance to TKIs
treatment is aberrant expression of BCL6, a TF that represses the p53 pathway at multiple
levels and has been shown to be induced by treatment with TKIs in Ph+ ALL [67]. In
addition, an important role in TKI resistance is played by the microenvironment since the
stromal support in vitro was capable of fostering the outgrowth of dasatinib-resistant Ph+
ALL cells [68]. Such growth-promoting effect by the microenvironment may be due to the
expression of CXCL12 and IL-7 which, in turn, protect Ph+ ALL cells against the effects
of TKIs [69].
3.3. C. Chemotherapy-Free Treatment
The current therapeutic regimen for Ph+ ALL, the combination of chemotherapy with
TKIs, does not overcome the major hazard of each individual treatment which are toxicity
and development of resistance mutations in the BCR-ABL1 gene.
Chemotherapy-induced myelotoxicity leads to infections which are responsible for
death of 10–20% of adult patients and of a higher percentage of the elderly ones. The
majority of relapses in Ph+ ALL patients treated with chemotherapy and TKIs is caused by
BCR-ABL mutations, in particular T315I.
In an attempt to improve the outcome of Ph+ ALL, a chemotherapy-free approach
consisting of dasatinib and corticosteroids followed by two cycles of blinatumomab, a
bi-specific T-cell engager antibody that recruits T cells to CD19+ B-cells, was recently
investigated in a phase 2 clinical trial of newly diagnosed Ph+ ALL patients [70]. This
therapeutic approach led to complete remission and molecular response in 98 and 60%
of the patients, respectively, with an 18-month overall survival in 95% of the patients.
The clinical outcomes of this clinical trial are very encouraging, but its long-term benefits
are unclear since relapses occurred in patients with IKZF1 deletions and poor-prognosis
secondary mutations (CDKN2A or CDKN2B). In addition, some of these patients exhibited
the outgrowth of clonal leukemic populations carrying the T315I BCR-ABL mutation.
The results of this clinical trial compare favorably to the ponatinib/chemotherapy
combination trial which was associated with notable toxic effects [71]. However, a longer
follow-up of a larger cohort of Ph+ ALL patients treated with this chemotherapy-free
regimen, in particular those also receiving a bone marrow transplant as consolidation

Genes 2021, 12, 1355

7 of 18

therapy, is needed to determine whether this approach will replace the chemotherapy/TKIs
combination as standard of care for Ph+ ALL.
A summary of treatment regimens in adults with Ph+ ALL is presented in Figure 2.

Figure 2. Treatment of adults with Philadelphia positive B-cell ALL. HSCT, hematopoietic stem cell
transplant; TKI, tyrosine kinase inhibitor.

4. Role of the MYB-CDK6 Pathway in Ph+ ALL Cells
Several therapeutic options exist for patients with Ph+ ALL but the outcome for a significant portion of them, especially those with TKI-resistant disease, remains dismal. For this
reason, we have investigated for many years the biology of Ph+ ALL, in search of vulnerabilities of leukemic cells that might be exploited therapeutically [72–75]. The transcription factor
MYB (also known as c-MYB), and the MYB-CDK6 axis, have been thoroughly investigated by
us and others and constitute a promising therapeutic target [76–78].
BCR-ABL-transformed B-cells are “addicted” to the expression of MYB [78], similar to
BCR-ABL1-transformed myeloid cells, AML cells and a subset of T-ALL cells [79–81].
Upon assessing the changes in gene expression induced by MYB silencing, we noted
that levels of cyclin D3, CDK6 and E2F-regulated genes were markedly decreased in MYBsilenced Ph+ ALL cells [78]. Such changes suggest that MYB silencing impairs CDK6
activity, blocking E2F activation and S phase entry. Indeed, by selectively silencing the
expression of either CDK6 or the related CDK4 kinase, we noted that the growth of Ph+
ALL cells was suppressed upon CDK6 but not CDK4 silencing. The precise mechanism
responsible for the selective requirement of CDK6 by Ph+ ALL cells is unknown; however,
CDK6 is predominantly localized in the nucleus, whereas CDK4 is exclusively localized in
the cytoplasm of Ph+ ALL cells, possibly explaining why its expression is dispensable for
Ph+ ALL growth [78].
Thus, targeting MYB or relevant MYB-regulated pathways that rely upon CDK6
activity might represent an attractive therapeutic strategy, especially for relapsed/TKIresistant Ph+ ALL.
In recent years, several candidate MYB inhibitors were identified including parthenolide, naphthol AS-E phosphate, and celastrol [82–84]. However, none of these compounds
has been tested clinically and their growth-suppressive effects in BCR-ABL-expressing
cells may not be entirely specific due to multiple mechanisms of action of these compounds [83,85–87].
MYB-dependent transcription and AML cell growth was also suppressed by a nonfunctional peptide that disrupts the interaction of MYB with TAF1, an essential component
of the general transcriptional co-activating complexes TFIID and SAGA [88]. However, it
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is unclear if this is a viable therapeutic approach, given potential pleiotropic side effects
induced by targeting a general transcriptional co-activator.
MYB expression is required for the proliferation and survival of normal and leukemic
hematopoietic cells [89,90] and the interaction of MYB with the p300 acetyltransferase
protein is required for MYB-dependent transformation ex vivo [91] and for induction
of AML by several oncogenes [92]. Thus, it has been hypothesized that blocking the
MYB-p300 interaction may have therapeutic value for the treatment of MYB-dependent
leukemia [77,93].
Several candidate compounds that disrupt this interaction were identified [84,94,95],
but preliminary data of in vivo efficacy exist only in mice injected with MLL-rearranged
AML cells and treated with a peptidomimetic inhibitor of the MYB-p300 interaction [95].
Thus, further assessment of the anti-leukemia effects of these inhibitors of MYB function
is needed.
Based on our findings that MYB silencing in Ph+ ALL cells induces a marked decrease
in CDK6 expression/activity with no effects on CDK4 levels [78], we reasoned that targeting
CDK6 with a CDK4/CDK6 inhibitor [96,97] may mimic key biological effects induced by
MYB down-regulation. Indeed, pharmacological inhibition of CDK6 activity with the
CDK4/6 inhibitor palbociclib suppressed growth of Ph+ ALL cells ex vivo and in mice [78].
The regulation of cell cycle progression in eukaryotic cells is accomplished by changes
in the activity of cyclin-cyclin dependent kinases (CDK) complexes. While the expression
of CDK proteins is relatively constant throughout the cell cycle, cyclins levels change
in response to proliferative signals, resulting in the activation of different cyclin-CDK
complexes in different phases of the cell cycle. The G1 to S phase progression through the
so-called “restriction point” determines the commitment of cells to divide and is signaled
by increased activity of CDK4/CDK6 in complex with D-type cyclins [98]. The primary
role of CDK4/CDK6 is to phosphorylate and inhibit the Retinoblastoma (RB) protein
and its homologs RBL1 and RBL2, promoting the activation of the E2F TFs, which is
followed by CDK2 activation and the initiation of DNA replication [99]. The existence
of multiple CDK and cyclin genes (13 and 25 respectively, although only 4 CDK and
10 CYCLIN genes are directly involved in cell cycle regulation) allows for the regulation
of cell proliferation in specific contexts, while, at the same time, providing redundancy
as suggested by the fact that single deletion of most CDK genes (except for CDK1) or
cyclin genes has negligible effects in most cells. On the other hand, cancer cells are often
characterized by mutations leading to hyperactivation of specific cyclin-CDK complexes,
which might constitute potential candidates for targeted therapies [100]. Consistent with
these ideas, the deletion of CDK6 caused only moderate reduction in the number of most
hematopoietic cells, with decreased cellularity of the spleen and the thymus [101]. These
effects were not associated with serious phenotypic abnormalities. Interestingly, even the
combined deletion of CDK4 and CDK6 allowed the proliferation of mouse embryonic
fibroblasts and development up to the late embryonic stage, at which point hematological
defects became significant [101]. In hematopoietic stem cells, CDK6 expression regulates
the time to exit from quiescence but is not necessary in cycling cells [102]. In addition, CDK6
has been suggested to be important under stress conditions (such as during transplantation)
but not during normal hematopoiesis [103]. Conversely, CDK6 activity is often increased
by various mechanisms in tumors, especially in hematological malignancies. CDK6 was
found to be uniformly overexpressed in T-cell leukemia/lymphoma in the absence of gene
amplification [104], and higher expression of CDK6 but not CDK4 was observed in B-ALL
cells in comparison to normal bone marrow cells [105]. The CDK6 locus is amplified in
up to 23% of cases of T-cell lymphoma [106]. In addition, several studies found that in a
fraction of B- and T-cell malignancies, aberrant RAG-induced recombination result in the
t(2;7) translocation that juxtaposes the immunoglobulin light chain locus to the CDK6 locus
driving CDK6 expression [107–109]. Moreover, CDK6 is negatively regulated by miR-124
which is suppressed by promoter methylation in ALL cells and this event is associated with
worse clinical outcome [110]. In BCR-ABL transformed cells, JUN activation prevents CDK6
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promoter methylation which is a limiting factor for leukemogenesis [111] and finally in 30%
to 50% Ph+ ALL cases the CDKN2A locus is deleted, removing the inhibition of CDK6 by
p16-INK4A [63,65]. Altogether, these studies suggest that in hematological malignancies,
CDK6 has an important role in the regulation of cell proliferation. In agreement with this
view, two studies showed that CDK6 but not CDK4 is required for the proliferation of
MLL-rearranged leukemia, despite the fact that both kinases are expressed [105,112].
While CDK6 activity promotes cell cycle progression, multiple lines of evidence
indicate that CDK6 exerts other activities, some of which kinase-independent, that may be
important for the phenotype of leukemic cells.
Firstly, CDK6 has been shown to block differentiation of myeloid cells [112,113] and
this may be due to interaction with and inhibition of RUNX1 [114]; at the same time, CDK6
can phosphorylate and potentiate RUNX1 transactivation potential, promoting cell proliferation [115]. These findings suggest that CDK6 regulates RUNX1 by two mechanisms
(physical interaction and phosphorylation) that might be alternatively utilized during differentiation and proliferation. In support for the importance of CDK6 activity in leukemia,
an unbiased cDNA screen identified CDK6 as a gene promoting imatinib resistance in
v-ABL transformed cells. Furthermore, CDK6 was found to phosphorylate the transcription factor FOXM1 and prevent its ubiquitin-dependent degradation [110]. FOXM1 is a
particularly interesting target because of its multiple oncogenic roles in different types
of cancer [116] including B-ALL [117]. In addition to regulating transcription trough
RB/E2F and FOXM1, CDK6 has been reported to act as a transcription (co)-factor (CDK6
lacks a DNA-binding motif). In this role, CDK6 regulates the expression of EGR1 [103],
VEGF and p16INK4A [111] and several genes of the p53 pathway [118]. Finally, CDK6
activity modulates the metabolism of T-ALL cells by phosphorylating and inhibiting 6phosphofructokinase and pyruvate kinase M2, inducing a protective antioxidant function
that prevents ROS-dependent cell death [119]. We and others have shown that inhibition of
CDK6 activity is associated with changes in the transcription of various genes. While some
of these effects are due to regulation of the activity/stability of transcription factors such as
RB/E2F and FOXM1, studies from the Sexl laboratory have shown a direct transcriptional
role for CDK6 in the regulation of genes important for hematopoiesis and leukemogenesis [103,120] as well as several regulators of p53 function [118]. Most of these genes were
shown to be regulated in a kinase-independent manner.
Palbociclib inhibits CDK6 activity but cannot suppress CDK6 expression; in fact, we
observed a compensatory CDK6 up-regulation after Palbociclib treatment [78]. This increase in CDK6 levels might be associated to enhanced kinase-independent transcriptional
activation and might also result in resistance to palbociclib treatment, given that in clinical
trials, palbociclib peak plasma concentration is not much higher than that necessary for
effective inhibition of RB phosphorylation in vitro [121].
In summary, CDK6 does not function solely as a regulator of S-phase entry but can
affect cancer cells, in particular different types of leukemic cells, in a way that might be
exploited therapeutically.
5. Inhibiting CDK6 Expression by Proteolysis-Targeting Chimera (PROTACs)
Suppresses Ph+ ALL
Due to growing evidence suggesting that CDK6 has several pro-tumorigenic functions besides the regulation of the G1-S transition, agents that reduce CDK6 expression
are expected to suppress leukemia growth through canonical (kinase-dependent) and
non-canonical (kinase-independent) mechanisms. Moreover, such agents would also display fewer side effects compared to dual CDK4/6 inhibitors as normal hematopoietic
progenitors rely on both CDK4 and CDK6 for their growth.
Designing a CDK6-selective ATP competitive inhibitor devoid of activity toward
CDK4 is challenging because the ATP binding domain (where typical small molecule
inhibitors bind) of human CDK4 and CDK6 is virtually identical, except for a Glu21 of
CDK6 that is replaced by Val14 in CDK4. Moreover, such compound would not inhibit the
kinase-independent effects of CDK6.
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Proteolysis-targeting chimeras (PROTACs) represent a new paradigm in pharmacology with the potential to be highly effective anti-cancer therapeutic agents. PROTACs
are bi-functional molecules comprised of a targeting arm directed towards the protein of
interest and an E3 ligase-recruiting arm connected by a linker; this allows the recruitment
of various E3 ligases for optimal ubiquitination and proteasomal degradation of the protein
of interest [122,123]. Compared to a traditional competitive inhibitor, a PROTAC requires
less drug exposure due to its catalytic mechanism, where it binds a substrate, recruits an E3
ligase for ubiquitination/proteasomal degradation, and is released to repeat the cycle [124].
In contrast, a competitive inhibitor is required to bind continuously a non-degraded target
protein in order to inhibit its activity, thus requiring 10–50 fold excess drug exposures over
the IC50 to ensure effective inhibition [125].
Our group and others envisioned that selective CDK6-PROTACs could be developed
due to differences in exposed lysine residues between CDK4 and CDK6, making it possible
to identify CDK4/6-targeted PROTACs with preferential poly-ubiquitinatination and proteasomal degradation of one of the two related kinases. Therefore, discovery efforts were
undertaken to identify PROTACs that would selectively degrade CDK6 over CDK4 [126–128].
We reported the development of novel CDK6-targeting PROTACs consisting of highaffinity small molecule ligands for CDK4/6, and for the E3 ubiquitin ligase Cereblon, joined
by linkers of different structure and/or size [129].
In order to generate a suitable CDK6 targeting PROTAC a potent CDK6 ligand was
conjugated to an E3 ligase recruiting molecule, such as a thalidomide derivative, using
a suitable linker. We considered Palbociclib as a CDK6 targeting ligand since it potently
inhibits CDK6, it is an FDA approved CDK4/6 kinase inhibitor, and the X-ray crystal
structure of CDK6 in complex with Palbociclib is available (pdb ID 2euf) [130]. Palbociclib’s
piperazine moiety was suggested as optimal region to install a linker since the X-ray
structure reveals this moiety is protruding into solvent. Surprisingly this region was
sensitive to linker attachment and a variety of linkers and linkers with various E3 ligase
recruiting ligands were evaluated until we identified a Palbociclib conjugate that potently
inhibited CDK6 and preferentially degraded CDK6 compared side by side to CDK4 by
Western Blot analysis. The Cereblon-recruiting PROTAC YX-2-107 was identified as a potent
inhibitor of in vitro CDK4 or CDK6 kinase activity (IC50 = 0.69 and 4.4 nM, respectively)
comparable to Palbociclib (IC50 = 9.5 nM) as well as a selective CDK6 degrader in Ph+
BV173 ALL cells with a degradation constant, DC50, of ~4 nM, based on densitometric
analysis of CDK6 band intensities over a range of YX-2-107 concentrations [126].
In particular, one PROTAC termed YX-2-107 not only degraded rapidly and preferentially CDK6 over CDK4, but also inhibited CDK4/6 enzymatic activity in vitro with IC50
comparable to that of palbociclib (Figure 1). Of greater importance, PROTAC YX-2-107
exhibited kinase-dependent and independent effects in Ph+ cell lines, and suppressed
patient-derived Ph+ ALL growth in vivo, using immunodeficient (NSG) mice.
Initial evidence in support of CDK6 kinase-independent effects in Ph+ ALL came
from the comparison of the effects induced by CDK6-silencing vs CDK6 inhibition [126].
We observed that CDK6-silenced Ph+ ALL cells are more susceptible to apoptosis and
exhibit a slower disease progression in NSG mice than the palbociclib-treated counterparts,
possibly as consequence of lower expression of genes involved in cell survival, chromatin
remodeling and mitochondrial metabolic pathways for energy production observed in
CDK6-silenced cells. Interestingly, the expression of CDK6 and HDAC1 was highly correlated in a dataset of 122 Ph+ ALL patient’s samples, suggesting that the CDK6-HDAC1
pathway may be critical for the growth suppression/apoptosis of CDK6-silenced Ph+ ALL
cells. Together, these features of CDK6-silenced Ph+ cells support the idea that CDK6
degraders might be more effective therapeutic agents than CDK4/6 enzymatic inhibitors
because the latter drugs are predominantly cytostatic whereas CDK6 degraders are also
cytotoxic (Figure 3).
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suppress the expression of the CDK4/6 substrates phospho-RB and FOXM1, and induce
the preferential degradation of CDK6 over CDK4. A long-term (2–3 weeks) treatment of
NSG mice injected with de novo or TKI-resistant primary Ph+ ALL induced a marked
suppression of peripheral blood leukemia load that was comparable or even superior to
that induced by treatment with palbociclib. PROTAC YX-2-107 was also highly effective in
suppressing the growth of a TKI-resistant Ph+ ALL in human cytokine-expressing NRG
mice [126]. This finding suggests that neither pharmacological resistance to TKIs, nor
exposure to cytokines present in the human microenvironment impairs the therapeutic
effects of PROTAC-based CDK6 degraders.
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These in vivo effects represent the first demonstration of therapeutic efficacy by a
PROTAC that targets an oncogenic protein which exerts kinase-dependent and independent effects.
6. Future Approaches for CDK6-Targeted Therapies in Ph+ ALL
While suppressing CDK6 expression alone exerts anti-leukemia effects in our preclinical studies in mice injected with primary Ph+ ALL cells, treatment with PROTAC
YX-2-107 may not achieve a long-lasting therapeutic response. To address this potential
problem, we have generated derivatives of PROTAC YX-2-107 that are more potent in
inhibiting S phase and in inducing CDK6 degradation or possess better metabolic stability. Further development is expected to yield second-generation PROTACs combining
superior ex vivo activities (inhibition of CDK6-regulated S phase; CDK6 degradation)
with improved pharmacokinetic properties that might establish these drugs as bona fide
anti-cancer therapeutics.
Other compounds may collaborate with CDK6-degrading agents in suppressing more
profoundly Ph+ ALL by targeting additional pathways that are essential for the growth of
these cells. For example, BET inhibitors are known to suppress the transcription of several
genes (e.g., CDK6 itself, BCL2 and MYC) which are all required for the growth of Ph+ ALL
cells. Incidentally, the expression of these three genes is transcriptionally regulated by
MYB which is also a target of BET inhibitors in leukemic cells due the involvement of
“superenhancers” in regulating its transcription [132].
We have also shown that CDK6 inhibition result in increased levels of apoptosis when
combined with the pan-BCL2 inhibitor Sabutoclax, in agreement with the reported activity
of CDK6 in regulating several genes with a role in cell survival.
An area that merits further investigation is the search for agents that result in synergistic effects when combined with CDK6 inhibition. It was previously shown that CDK6
expression confers resistance to Imatinib treatment [133]. It would be interesting to evaluate
whether CDK6 inhibitors can cooperate with TKIs in inducing a more profound clearance
of leukemic cells and possibly increasing the likelihood of achieving MRD-negative status,
which is a powerful predictor of response to therapy in ALL [42,134].
Another potential approach would be to combine a CDK6-selective PROTAC with
dexamethasone since the latter was shown to regulate the expression of MYB, BCL2 and BIM
in preclinical models of ALL [135]. Interestingly, two recent studies have shown synergistic
effects for the combination of Ribociclib (another CDK4/6 inhibitor) and dexamethasone
in Ph-negative B-ALL and T-ALL respectively [136,137].
Since the “MYB addiction” of Ph+ ALL is not only due to CDK6 expression but
also to other MYB-regulated genes such as BCL2, an alternative therapeutic strategy for
Ph+ ALL is to combine a CDK6-selective PROTAC with a selective BCL2 antagonist like
Venetoclax. This approach could be personalized by pre-selecting Ph+ ALL patients for
whom there is evidence that their leukemic cells undergo apoptosis ex vivo upon treatment
with Venetoclax.
In conclusion, these potential CDK6-based therapies may provide additional opportunities for an effective and less toxic therapeutic regimen for Ph+ ALL, especially the
TKI-resistant/refractory stage.
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